American Journal of Cardiology
Volume 103, Issue 9 , Pages 1196-1203 , 1 May 2009

Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non–ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial)

  • Alexandra J. Lansky, MD

      Affiliations

    • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
    • Corresponding Author InformationCorresponding author: Tel: 212-851-9320; fax: 212-851-9321
    • ,
  • Roxana Mehran, MD

      Affiliations

    • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
    • ,
  • Ecatarina Cristea, MD

      Affiliations

    • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
    • ,
  • Helen Parise, ScD

      Affiliations

    • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
    • ,
  • Frederick Feit, MD

      Affiliations

    • New York University School of Medicine, New York, New York
    • ,
  • E. Magnus Ohman, MD

      Affiliations

    • Department of Medicine, Duke University School of Medicine, Durham, North Carolina
    • ,
  • Harvey D. White, MD

      Affiliations

    • Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
    • ,
  • Karen P. Alexander, MD

      Affiliations

    • Department of Medicine, Duke University School of Medicine, Durham, North Carolina
    • ,
  • Michel E. Bertrand, MD

      Affiliations

    • Hopital Cardiologique, Lille, France
    • ,
  • Walter Desmet, MD

      Affiliations

    • University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Martial Hamon, MD

      Affiliations

    • University Hospital, Normandy, France
    • ,
  • Gregg W. Stone, MD

      Affiliations

    • Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York

Received 3 December 2008 ,Revised 8 January 2009 ,Accepted 8 January 2009.

References 

  1. Elsaesser A, Hamm CW. Acute coronary syndrome: the risk of being female. Circulation. 2004;109:565–567
  2. Lansky AJ, Pietras C, Costa RA, Tsuchiya Y, Brodie BR, Cox DA, et al Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction. Circulation. 2005;111:1611–1618
  3. Peterson ED, Lansky AJ, Kramer J, Anstrom K, Lanzilotta MJ National Cardiovascular Network Clinical Investigators. Effect of gender on the outcomes of contemporary percutaneous coronary intervention. Am J Cardiol. 2001;88:359–364
  4. Malenka DJ, Wennberg DE, Quinton HA, O'Rourke DJ, McGrath PD, Shubrooks SJ, et al Gender-related changes in the practice and outcomes of percutaneous coronary interventions in Northern New England from 1994–1999. J Am Coll Cardiol. 2002;40:2092–2101
  5. Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J. 2003;24:1815–1823
  6. Alexander KP, Chen AY, Newby LK, Schwartz JB, Redberg RF, Hochman JS, et al. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. Circulation. 2006;114:1380–1387
  7. Iakovou I, Dangas G, Mehran R, Lansky AJ, Kobayashi Y, Adamian M, et al. Gender differences in clinical outcome after coronary artery stenting with use of glycoprotein IIb/IIIa inhibitors. Am J Cardiol. 2002;89:976–979
  8. Watanabe CT, Maynard C, Ritchie JL. Comparison of short-term outcomes following coronary artery stenting in men versus women. Am J Cardiol. 2001;88:848–852
  9. Boersma E, Harrington RA, Moliterno DJ, White H, Théroux P, Van de Werf F, et al Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189–198
  10. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, et al Bivalirudin for patients with acute coronary syndromes. N Eng J Med. 2006;355:2203–2216
  11. Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, et al Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA. 2007;298:2497–2506
  12. American Heart Association Heart disease and stroke statistics—2007 update. Circulation. 2007;115(suppl):e69–e171
  13. Merz CNB, Shaw LJ, Reis SE, Bittner V, Kelsey SF, Olson M. Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) study. J Am Coll Cardiol. 2006;47(suppl):21S–29S
  14. Pepine CJ, Kerensky RA, Lambert CR, Smith KM, von Mering GO, Sopko G, et al. Some thoughts on the vasculopathy of women with ischemic heart disease. J Am Coll Cardiol. 2006;47(suppl):30S–35S
  15. Wenger NK, Speroff L, Packard B. Cardiovascular health and disease in women. N Engl J Med. 1993;329:247–256
  16. The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436–443
  17. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusuf S. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet. 2000;355:1936–1942
  18. Fragmin and Fast Revascularization During Instability in Coronary Artery Disease (FRISC II) Investigators. Long-term low-molecular-mass heparin in unstable coronary artery disease: FRISC II prospective randomized multicentre study. Lancet. 1999;354:701–707
  19. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non–ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108–3116
  20. Dauerman HL, Andreou C, Perras MA, Spinner JS, Lessard D, Weiner BH. Predictors of bleeding complications after rescue coronary interventions. J Thromb Thrombolysis. 2000;10:83–88
  21. Lenderink T, Boersma E, Ruzyllo W, Widimsky P, Ohman EM, Armstrong PW, et al. Bleeding events with abciximab in acute coronary syndromes without early revascularization: an analysis of GUSTO IV-ACS. Am Heart J. 2004;147:865–873
  22. The GUSTO-IV ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularization: the GUSTO-IV-ACS randomized trial. Lancet. 2001;357:1915–1924
  23. Fernandes LS, Tcheng JE, O'Shea JC, Weiner B, Lorenz TJ, Pacchiana C, et al Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention? (Lessons from the ESPRIT study). J Am Coll Cardiol. 2002;40:1085–1091
  24. Mehilli J, Kastrati A, Dirschinger J, Bollwein H, Neumann FJ, Schomig A. Differences in prognostic factors and outcomes between women and men undergoing coronary artery stenting. JAMA. 2000;284:1799–1805
  25. Trabattoni D, Bartorelli AL, Montorsi P, Fabbiocchi F, Loaldi A, Galli S, et al Comparison of outcomes in women and men treated with coronary stent implantation. Catheter Cardiovasc Interv. 2003;58:20–28
  26. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, et al. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol. 2005;96:1200–1206
  27. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, et al Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol. 2003;92:930–935
  28. Feit F, Voeltz MD, Attubato MJ, Lincoff AM, Chew DP, Bittl JA, et al. Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention: an analysis of the REPLACE-2 trial. Am J Cardiol. 2007;100:1364–1369
  29. Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, et al. Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial. Am Heart J. 2006;151(suppl):1032.e1–1032.e7
  30. Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, et al Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;49:1362–1368

 The ACUITY trial was sponsored by The Medicines Company, Parsippany, NJ.

PII: S0002-9149(09)00125-8

doi: 10.1016/j.amjcard.2009.01.030

American Journal of Cardiology
Volume 103, Issue 9 , Pages 1196-1203 , 1 May 2009

Article Tools

* Image Usage & Resolution